chronic fatigu syndrom treatment tz wlu neurolog disord ailment unknown etiolog immun system disord syndrom treatment chronic fatigu syndrom cf variabl uncertain condit manag cure treatment includ medic medic treatment complementari altern medicin sytemat review cf patient suscept placebo effect predict low placebo respons compar patient diseas cf associ chemic sensit patient respond lower dose medic compar patient medic treatment antidepress antidepress prescrib cf patient purpos treat secondari depress mood swing low dosag tricycl antidepress prescrib improv sleep qualiti reduc pain antidepress side effect increas cf symptom baselin metabol differ patient find antidepress help individu patient matter trial error studi antidepress cf mix studi reduct symptom antidepress benefit autonom nervou system stimul drug atomoxetin strattera stimul autonom nervou system appear posit effect peopl cf symptom amphetamin amphetamin analog help patient exampl methylphenid ritalin better placebo reliev fatigu concentr disturb minor cf patient need long term effect modafinil provigil medic design aid maintain wake posit individu cf properli studi small studi suggest longterm treatment modafinil benefici cf patient hormon hormon time time includ steroid cortisol thyroid hormon studi perform dr jacob teitelbaum dr kent holtorf incorpor lowdos cortisol therapi demonstr posit review publish endocr rev apr clear compar hydrocortison trial cf patient placebo control trial carri mckenzi al publish jama sep cdc defin patient comorbid psychiatr diagnosi triall hydrocortison daili month moder benefit global health scale specif measur fatigu disabl adren suppress natur function patient hydrocortison second studi publish lancet feb clear al randomis crossov trial cdc patient comorbid psychiatr condit lower dose day activ treatment chosen repres dose replac observ reduct ufc previou studi clinic fall fatigu score activ treatment return level fatigu popul median score compar placebo larg reduct selfrat disabl score fatigu improv dose hydrocortison adren suppress seriou advers effect review conclud second treatment studi short term posit effect wore rapidli switch placebo routin strategi treatment recommend evalu subsequ studi publish med jun blockman al perform month random placebocontrol doubleblind crossov studi patient fulfil cdc criteria chronic fatigu syndrom combin therapi mgd hydrocortison microgday alfafludrocortison month activ treatment conclud lowdos combin therapi hydrocortison fludrocortison effect patient chronic fatigu syndrom review studi publish journal chronic fatigu syndrom februari kent holtorf review previou hydrocortison trial safeti effect conclud treatment low physiolog dose cortisol safe effect routin dynam acth test adequ diagnost sensit reason therapeut trial physiolog dose cortisol major patient cf fm symptom consist adren dysfunct low blood pressur baselin cortisol level low lownorm rang immunoglobulin treatment role intraven immuno gammaglobulin ivigg manag cf unclear randomis doubl blind placebo control studi examin immunoglobulin short term efficaci follow studi year trial posit lloyd al publish med random doubleblind placebocontrol trial determin effect highdos ivigg fortynin patient abnorm cellmedi immun particip gkgmonth month effect produc remiss immunolog improv adult patient cf australian criteria year wilson al respond improv continu improv includ consid respond month peterson al publish med doubleblind placebocontrol trial iv igg thirti patient cf enrol observ differ group cdc criteria treat gkg placebo day month studi therapeut benefit detect term symptom amelior improv function statu despit restor igg level normal rang major advers experi observ iv igg placebo group row ks publish psychiatr re doubl blind random control trial young adolesc diagnos cdc defin cf test efficaci ivigg studi gmkgmonth placebo month followup month differ demonstr baselin function score month followup function outcom month advers effect common activ placebo solut predict respons followup studi year year respons deteri function time young peopl continu improv number disabl studi vollmer conna al publish med ninetynin adult patient fulfil diagnost criteria cf australian criteria cdc particip doubleblind random placebocontrol trial patient receiv intraven infus placebo solut three dose immunoglobulin gkg monthli basi month dose intraven immunoglobulin associ specif therapeut benefit advers reaction typic constitut symptom report patient relationship immunoglobulin treatment apart criteria select patient subgroup trial review comment mix trial peterson al observ differ group trial subject complet studi subject type ii error small sampl size volmaconnor al variabl dosag demonstr differt month month followup short period differ month row adolesc studi month differ immun modul treatment treatment staphylococc vaccin fibromyalgiachron fatigu syndrom patient increas serolog respons respons improv clinic outcom rct trial conduct improv regular inject continu maintain benefit andersson al publish journal eur pain small studi cf patient compar vaccin staphylococcu toxoid inject steril water clinic global impress improv vaccinetr group followup studi patient vaccin treatment continu year fifti percent rehabilit resum halftim fulltim work zachrisson al publish journal eur pain studi consecut refer patient fulfil acr criteria fm cdc criteria cf enrol randomis control trial receiv activ drug placebo treatment includ weekli inject sb staphylococcu toxoid colour steril water booster dose weekli total month treatment well toler intentiontotreat analysi respond sb group compar placebo group sixteen patient sb group reduc cpr score compar patient placebo group increas cpr symptom withdraw sb group mainten treatment requir prevent relaps titrat drug hormon supplement jacob teitelbaum al publish journal chronic fatigu syndrom randomis doubl blind placebo control intent treat studi seventytwo fm patient thirtyeight activ thirtyfour placebo sixtynin met cf cdc criteria receiv activ placebo therapi unifi intervent patient treat indic symptom andor lab test subclin thyroid gonad andor adren insuffici disord sleep suspect neural mediat hypotens nmh opportunist infect suspect nutrit defici patient receiv activ placebo treatment unifi intervent patient receiv sleep melatonin valerium rest mix individu basi low dose sleep medic high dose singl agent adjust patient hour uninterrupt sleep wake day sedat nutrit support multivitamin magnesium malic acid addit treatment individu base test clinic histori includ ferrou fumar vitamin levothyroxin synthroid desicc thyroid cortisol cortef dhea testosteron enanth delatestryl male natur testosteron femal estrogen replac uteru natur progesteron femal oxytocin fludrocortison florinef increas dietari salt water potassium sertralin zoloft paroxetin paxil fluoxetin prozac nefazodon serzon nystatin sever case itraconazol sporanox metronidazol flagyl iodoquinol yodoxin doxycyclin time studi antidepress serotonin uptak inhibitor ssri amitriptylin cyclobenzaprin patient group drop side effect group drop reason final visit sixteen activ patient better fourteen better wors wors versu three eleven placebo group cochranmantelhaenszel trend test improv fm impact questionnair fiq score decreas versu analog score improv versu random effect regress tender point tpi versu baselin adjust linear model longterm followup year activ group continu increas improv time despit patient wean treatment analys antidepress impact primari comparison activ placebo treatment nadh treatment forsyth al publish ann allergi asthma immunol random doubleblind placebocontrol crossov studi patient cf evalu efficaci reduc form nicotinamid adenin dinucleotid nadh twentysix elig patient fulfil cdc criteria cf complet studi subject randomli assign receiv nadh placebo week period week washout period subject cross altern regimen final week period sever advers effect observ studi drug patient respond favor nadh contrast placebo santaella al report health sci randomis studi compar oral therapi reduc nicotinamid adenin dinucleotid nadh convent modal treatment patient cf total patient fulfil cdc criteria cf randomli assign nadh nutrit supplement psycholog therapi month twelv patient receiv nadh dramat statist reduct symptom score trimest author conclud observ effect nadh convent treatment trimest trial trend improv modal subsequ trimest warrant assess larger patient sampl medic treatment allergi identif treatment case cfslike symptom caus allergi enzym defici food intoler chronic sinus coeliac diseas irrit bowel syndrom allergi test treatment elimin diet prove benefici complementari altern medicin essenti fatti acid treatment number studi carri supplement oil deriv essenti fatti acid omega gamma linolen acid gla omega eicosapentaeno acid epa docosahexaeno acid dha studi efamol marin compris even primros oil gla fishoil concentr epa dha behan behan report randomis doubl blind placebo control studi patient post viral fatigu syndrom pvf supplement morn even week patient activ treatment placebo oliv oil report improv symptom exhaust ach pain muscl weak lack concentr dizzi vertigo depress memori loss patient activ treatment record fewer episod cardiac palpit tachycardia symptom statist improv behan horribin enrol sixtythre adult diagnosi pvf randomis doubleblind placebocontrol studi month patient activ treatment supplement placebo paraffin oil report improv improv symptom fatigu ach pain muscl weak lack concentr dizzi vertigo depress memori loss symptom statist improv test supplement group cellular membran phospholipid efa feedstock return normal doubl blind control studi warren al report fifti patient fulfil oxford criteria cf neglig pretreat differ redcel membran rbc lipid compar control studi differ treat placebo patient oppos previou studi patient subgroup question remain sunflow oil placebo therapeut effect review cf treatment reid al compar behanhorrobin warren studi conclud mix classifi dietari supplement unknown effect magnesium cox al publish lancet randomis doubleblind placebocontrol trial magnesium cf associ casecontrol studi patient cf lower red cell magnesium concentr healthi control subject clinic trial patient cf randomli alloc intramuscular magnesium sulphat week week patient placebo patient treat magnesium improv energi level better emot pain judg chang nottingham health profil treat patient benefit treatment patient energi score improv contrast patient placebo felt better differ ci placebo patient better energi score red cell magnesium return normal patient magnesium patient placebo review reid al determin subsequ studi fail find defici magnesium peopl chronic fatigu syndrom magnesium treatment dietari supplement unknown effect review werbach nutrit strategi treat chronic fatigu syndrom compar studi conclud margin magnesium defici cf comment trial find consist report cf patient magnesiumdefici fail benefit inject magnesium time dosag receiv group magnesium defici patient benefit trial conclus margin defici contribut clinic manifest chronic fatigu syndrom detriment heal process feasibl identifi object test resolut assur repeat test initi treatment rariti seriou advers reaction difficulti rule margin defici therapeut benefit nutrit supplement appear pharmacolog effect ration consid supplement cf patient nutrient carnitin treatment number random control trial find benefit supplement carnitin ester cdc defin cf trial random crossov design compar lcarnitin amantadin cf patient met cdc criteria medicin month week washout period lcarnitin time daili statist clinic improv studi paramet week treatment clinic paramet deterior greatest improv place week lcarnitin treatment randomis control trial cdc defin patient compar acetyllcarnitin propionyllcarnitin combin group cf patient week treatment consider improv patient acetylcarnitin group propionylcarnitin group combin group acetylcarnitin improv mental fatigu propionylcarnitin improv gener fatigu attent concentr improv group pain complaint decreas group week finish treatment worsen fatigu experienc group acetylcarnitin group group chang plasma carnitin level correl clinic improv randomis control trial elderli patient met cdc criteria cf psychiatr disord placebo carnitin supplement activ group greater improv measur placebo group paramet muscl pain prolong fatigu exercis sleep disord physic fatigu mental fatigu fatigu sever scale function statu mini mental examin mmse improv complementari altern medicin usag studi report increas util altern treatment peopl cf studi design assess altern medicin perceiv benefit pair cf noncf cotwin twin cf cf altern treatment life larg proport twin consid help futur ascertain altern practic manag cf refer rime ka chalder treatment chronic fatigu syndrom occup medicin doi occmedkqi pmid cho hj hotopf wess placebo respons treatment chronic fatigu syndrom systemat review metaanalysi psychosom med doi psye pmid jason la taylor rr kennedi cl chronic fatigu syndrom fibromyalgia multipl chemic sensit communitybas sampl person chronic fatigu syndromelik symptom psychosom med pmid clauw dj potenti mechan chemic intoler condit ann acad sci pmid gruber aj hudson ji pope hg manag treatmentresist depress disord interfac psychiatri medicin fibromyalgia chronic fatigu syndrom migrain irrit bowel syndrom atyp facial pain premenstru dysphor disord psychiatr clin north pmid nation center infecti diseas treatment patient chronic fatigu syndrom htm center diseas control prevent retriev doctor guid chronic fatigu syndrom da capo press isbn thoma ma smith apan investig longterm benefit antidepress medic recoveri patient chronic fatigu syndrom hum psychopharmacol dec schonfeldtlecuona connemann bj wolf rc braun freudenmann rwbupropion augment treatment chronic fatigu syndrom coexist major depress episod pharmacopsychiatri jul goodnick pj sandov brickman klima ngbupropion treatment fluoxetineresist chronic fatigu syndrom psychiatri nov hicki ib wilson aj wright jm bennett bk wakefield lloyd ar random doubleblind placebocontrol trial moclobemid patient chronic fatigu syndrom clin psychiatri sep blockman persoon van houdenhov bobbaer methylphenid reduc symptom chronic fatigu syndrom med doi jamjm pmid randal dc cafferti fh shneerson jm smith llewelyn mb file se chronic treatment modafinil benefici patient chronic fatigu syndrom psychopharmacol doi pmid teitelbaum bird weiss gould lowdos hydrocortison chronic fatigu syndrom jama author repli doi jama pmid holtorf diagnos treatment hypothalamicpituitaryadren hpa axi dysfunct patient chronic fatigu syndrom cf fibromyalgia fm journal chronic fatigu syndrom doi jvn_ clear aj heap malhi gs wess okean miell februari lowdos hydrocortison chronic fatigu syndrom randomis crossov trial lancet doi pmid mckenzi ofallon dale al lowdos hydrocortison treatment chronic fatigu syndrom random control trial jama pmid blockman persoon van houdenhov lejeun bobbaer june combin therapi hydrocortison fludrocortison improv symptom chronic fatigu syndrom random placebocontrol doubleblind crossov studi med pmid clear aj april neuroendocrinolog chronic fatigu syndrom endocr rev pmid lloyd hicki wakefield boughton dwyer doubleblind placebocontrol trial intraven immunoglobulin therapi patient chronic fatigu syndrom med pmid holtorf diagnos treatment hypothalamicpituitaryadren hpa axi dysfunct patient chronic fatigu syndrom cf fibromyalgia fm journal chronic fatigu syndrom doi jvn_ peterson pk shepard macr al control trial intraven immunoglobulin chronic fatigu syndrom med pmid wilson hicki lloyd al longitudin studi outcom chronic fatigu syndrom bmj pmid row ks year followup young peopl cf doubl blind randomis control intraven gammaglobulin trial present confer clinic scientif basi cf sydney row ks doubleblind random control trial assess efficaci intraven gammaglobulin manag chronic fatigu syndrom adolesc psychiatr re pmid patarcamontero roberto chronic fatigu syndrom advanc epidemiolog clinic basic scienc haworth pr isbn vollmerconna hicki hadzipavlov al intraven immunoglobulin ineffect treatment patient chronic fatigu syndrom med pmid andersson bagbi jr dyrehag gottfri effect staphylococcu toxoid vaccin pain fatigu patient fibromyalgiachron fatigu syndrom eur pain pmid zachrisson colquenavarro gottfri cg regland mllbi februari immun modul staphylococc prepar fibromyalgiachron fatigu syndrom relat antibodi level clinic improv eur clin microbiol infect di doi pmid teitelbaum al journal chronic fatigu syndrom zachrisson regland jahreskog jonsson kron gottfri cg treatment staphylococcu toxoid fibromyalgiachron fatigu syndromea randomis control trial eur pain pmid naranch park yj repkaramirez ms velard clauw baraniuk jn tender sinu rhinosinus otolaryngologyhead neck surgeri offici journal american academi otolaryngologyhead neck surgeri doi mhn pmid baraniuk jn clauw dj gaumond rhiniti symptom chronic fatigu syndrom ann allergi asthma immunol pmid forsyth lm preuss hg macdowel al chiazz birkmay gd bellanti ja februari therapeut effect oral nadh symptom patient chronic fatigu syndrom ann allergi asthma immunol pmid santaella font disdier om june comparison oral nicotinamid adenin dinucleotid nadh versu convent therapi chronic fatigu syndrom health sci pmid aaron la burk mm buchwald overlap condit patient chronic fatigu syndrom fibromyalgia temporomandibular disord arch intern med pmid nightingal foundat goldstein jay byron hyde clinic scientif basi myalgic encephalomyelitischron fatigu syndrom ogdensburg ny nightingal foundat chapter role food intoler chronic fatigu syndrom isbn logan ac wong chronic fatigu syndrom oxid stress dietari modif altern medicin review journal clinic therapeut pmid mossmorri spenc lump split function somat syndrom infecti emot risk factor differenti onset chronic fatigu syndrom irrit bowel syndrom psychosomat medicin doi psi pmid behan po behan wm horrobin high dose essenti fatti acid postvir fatigu syndrom acta neurol scand pmid warren mckendrick peet role essenti fatti acid chronic fatigu syndrom casecontrol studi redcel membran essenti fatti acid efa placebocontrol treatment studi high dose efa acta neurol scand pmid carruth bm jain ak al myalgic encephomyel chronic fatigu syndrom clinic work case definit diagnost treatment protocol consensu document journal chronic fatigu syndrom omega essenti fatti acid pathophysiolog role clinic medicin york wileyliss isbn werbach april nutrit strategi treat chronic fatigu syndrom altern med rev pmid pliopli av pliopli amantadin lcarnitin treatment chronic fatigu syndrom neuropsychobiolog pmid reid chadler clear hotopf wess extract clinic evid chronic fatigu syndrom british medic journal cox campbel mj dowson red blood cell magnesium chronic fatigu syndrom lancet pmid afari eisenberg dm herrel al altern treatment chronic fatigu syndrom discord twin integr med pmid jone jf maloney em boneva rs jone ab reev wc complementari altern medic therapi util peopl chronic fatigu ill unit bmc complement altern med doi pmid malaguarnera gargant mp cristaldi al acetyl lcarnitin alc treatment elderli patient fatigu arch gerontol geriatr doi jarchger pmid vermeulen rc scholt hr exploratori open label random studi acetyl propionylcarnitin chronic fatigu syndrom psychosom med pmid chronic fatigu syndrom medic issu clinic descript etiolog pathophysiolog treatment manag societi histori histori altern name controversi outbreak cultur refer notabl patient sophia mirza